2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis by T. Briot et al.
2012 update of French guidelines for the pharmacological
treatment of postmenopausal osteoporosis
Submitted by a.bergoend on Mon, 04/27/2015 - 14:40
Titre 2012 update of French guidelines for the pharmacological treatment ofpostmenopausal osteoporosis
Type de
publication Article de revue
Auteur
Briot, Karine [1], Cortet, Bernard [2], Thomas, Thierry [3], Audran, Maurice [4],
Blain, Hubert [5], Breuil, Véronique [6], Chapuis, Laure [7], Chapurlat, Roland [8],
Fardellone, Patrice [9], Feron, Jean-Marc [10], Gauvain, Jean-Bernard [11],
Guggenbuhl, Pascal [12], Kolta, Sami [13], Lespessailles, Eric [14], Letombe,
Brigitte [15], Marcelli, Christian [16], Orcel, Philippe [17], Seret, Patrick [18],
Trémollières, Florence [19], Roux, Christian [20]
Editeur Elsevier Masson








revue Joint Bone Spine
ISSN 1778-7254
Mots-clés
Adult [21], Bone Density [22], Bone Density Conservation Agents [23], Evidence-
based medicine [24], Female [25], Fractures, Bone [26], France [27], Humans [28],




OBJECTIVES: To update the evidence-based position statement published by the
French National Authority for Health (HAS) in 2006 regarding the pharmacological
treatment of postmenopausal osteoporosis, under the auspices of the French
Society for Rheumatology and Groupe de Recherche et d'Information sur les
Ostéoporoses (GRIO), and with the participation of several learned societies
(Collège National des Gynécologues et Obstétriciens Français, Groupe d'Étude de la
Ménopause et du Vieillissement hormonal, Société Française de Chirurgie
Orthopédique, Société Française d'Endocrinologie, and Société Française de
Gériatrie et de Gérontologie).
METHODS: A multidisciplinary panel representing the spectrum of clinical
specialties involved in managing patients with postmenopausal osteoporosis
developed updated recommendations based on a systematic literature review
conducted according to the method advocated by the HAS.
RESULTS: The updated recommendations underline the need for osteoporosis
pharmacotherapy in women with a history of severe osteoporotic fracture. In these
patients, any osteoporosis medication can be used; however, zoledronic acid is the
preferred first-line medication after a hip fracture. In patients with non-severe
fractures or no fractures, the appropriateness of osteoporosis pharmacotherapy
depends on the bone mineral density and FRAX(®) values; any osteoporosis
medication can be used, but raloxifene and ibandronate should be reserved for
patients at low risk for peripheral fractures. Initially, osteoporosis pharmacotherapy
should be prescribed for 5 years. The results of the evaluation done at the end of
the 5-year period determine whether further treatment is in order.
CONCLUSIONS: These updated recommendations are intended to provide
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